A photosensitizer delivered by bispecific antibody redirected T lymphocytes enhances cytotoxicity against EpCAM-expressing carcinoma cells upon light irradiation

Blaudszun, André‐René; Moldenhauer, Gerhard; Schneider, Marc; Philippi, Anja

doi:10.1016/j.jconrel.2014.10.025

Cited by 9 publications

(4 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the moment first-line therapeutic treatments in progressed tumors include in the most cases surgery, chemo- as well as radiotherapies ( 501 ) (compare Figure 2 ). Those have been shown to induce DNA damage and to trigger senescence in cancer cells, a process known as therapy-induced senescence (TIS) ( 10 , 502 , 503 ).…”

Section: The Escape Of Cancer Stem Cells From Therapymentioning

confidence: 99%

Cancer Stem Cells—Origins and Biomarkers: Perspectives for Targeted Personalized Therapies

et al. 2020

Self Cite

View full text Add to dashboard Cite

The use of biomarkers in diagnosis, therapy and prognosis has gained increasing interest over the last decades. In particular, the analysis of biomarkers in cancer patients within the pre- and post-therapeutic period is required to identify several types of cells, which carry a risk for a disease progression and subsequent post-therapeutic relapse. Cancer stem cells (CSCs) are a subpopulation of tumor cells that can drive tumor initiation and can cause relapses. At the time point of tumor initiation, CSCs originate from either differentiated cells or adult tissue resident stem cells. Due to their importance, several biomarkers that characterize CSCs have been identified and correlated to diagnosis, therapy and prognosis. However, CSCs have been shown to display a high plasticity, which changes their phenotypic and functional appearance. Such changes are induced by chemo- and radiotherapeutics as well as senescent tumor cells, which cause alterations in the tumor microenvironment. Induction of senescence causes tumor shrinkage by modulating an anti-tumorigenic environment in which tumor cells undergo growth arrest and immune cells are attracted. Besides these positive effects after therapy, senescence can also have negative effects displayed post-therapeutically. These unfavorable effects can directly promote cancer stemness by increasing CSC plasticity phenotypes, by activating stemness pathways in non-CSCs, as well as by promoting senescence escape and subsequent activation of stemness pathways. At the end, all these effects can lead to tumor relapse and metastasis. This review provides an overview of the most frequently used CSC markers and their implementation as biomarkers by focussing on deadliest solid (lung, stomach, liver, breast and colorectal cancers) and hematological (acute myeloid leukemia, chronic myeloid leukemia) cancers. Furthermore, it gives examples on how the CSC markers might be influenced by therapeutics, such as chemo- and radiotherapy, and the tumor microenvironment. It points out, that it is crucial to identify and monitor residual CSCs, senescent tumor cells, and the pro-tumorigenic senescence-associated secretory phenotype in a therapy follow-up using specific biomarkers. As a future perspective, a targeted immune-mediated strategy using chimeric antigen receptor based approaches for the removal of remaining chemotherapy-resistant cells as well as CSCs in a personalized therapeutic approach are discussed.

show abstract

Section: The Escape Of Cancer Stem Cells From Therapymentioning

confidence: 99%

Cancer Stem Cells—Origins and Biomarkers: Perspectives for Targeted Personalized Therapies

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…When cocultivated with EpCAM-expressing human carcinoma cells, T lymphocytes induced the cytolytic activity, and at the same time photosensitizer was transferred to target cells. Consequently, significant improved cytotoxic capacity of photosensitizer boosted T cells was found after irradiation [ 64 ].…”

Section: Strategies For Enhancing Efficacy Of Pdt: Targeting Antitmentioning

confidence: 99%

Targeting Antitumor Immune Response for Enhancing the Efficacy of Photodynamic Therapy of Cancer: Recent Advances and Future Perspectives

Yang

Wang

2016

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is a minimally invasive therapeutic strategy for cancer treatment, which can destroy local tumor cells and induce systemic antitumor immune response, whereas, focusing on improving direct cytotoxicity to tumor cells treated by PDT, there is growing interest in developing approaches to further explore the immune stimulatory properties of PDT. In this review we summarize the current knowledge of the innate and adaptive immune responses induced by PDT against tumors, providing evidence showing PDT facilitated-antitumor immunity. Various immunotherapeutic approaches on different cells are reviewed for their effectiveness in improving the treatment efficiency in concert with PDT. Future perspectives are discussed for further enhancing PDT efficiency via intracellular targetable drug delivery as well as optimized experimental model development associated with the study of antitumor immune response.

show abstract

“…In this case, temoporfin served also as a fluorescence label for the carrier systems. On the other hand, bispecific antibody‐redirected T lymphocytes have been used as carrier vehicles for m THPP (577).…”

Section: Other Applicationsmentioning

confidence: 99%

The Photosensitizer Temoporfin (mTHPC) – Chemical, Pre‐clinical and Clinical Developments in the Last Decade^†^‡

Wiehe

Senge

2022

Photochem & Photobiology

View full text Add to dashboard Cite

This review follows the research, development and clinical applications of the photosensitizer 5,10,15,20-tetra(mhydroxyphenyl)chlorin (mTHPC, temoporfin) in photodynamic (cancer) therapy (PDT) and other medical applications. Temoporfin is the active substance in the medicinal product Foscanâ authorized in the EU for the palliative treatment of head and neck cancer. Chemistry, biochemistry and pharmacology, as well as clinical and other applications of temoporfin are addressed, including the extensive work that has been done on formulation development including liposomal formulations. The literature has been covered from 2009 to early 2022, thereby connecting it to the previous extensive review on this photosensitizer published in this journal [Senge, M. O. and J. C. Brandt (2011) Photochem. Photobiol. 87, 1240-1296] which followed its way from initial development to approval and clinical application.

show abstract

A photosensitizer delivered by bispecific antibody redirected T lymphocytes enhances cytotoxicity against EpCAM-expressing carcinoma cells upon light irradiation

Cited by 9 publications

References 47 publications

Cancer Stem Cells—Origins and Biomarkers: Perspectives for Targeted Personalized Therapies

Cancer Stem Cells—Origins and Biomarkers: Perspectives for Targeted Personalized Therapies

Targeting Antitumor Immune Response for Enhancing the Efficacy of Photodynamic Therapy of Cancer: Recent Advances and Future Perspectives

The Photosensitizer Temoporfin (mTHPC) – Chemical, Pre‐clinical and Clinical Developments in the Last Decade^†^‡

Contact Info

Product

Resources

About

A photosensitizer delivered by bispecific antibody redirected T lymphocytes enhances cytotoxicity against EpCAM-expressing carcinoma cells upon light irradiation

Cited by 9 publications

References 47 publications

Cancer Stem Cells—Origins and Biomarkers: Perspectives for Targeted Personalized Therapies

Cancer Stem Cells—Origins and Biomarkers: Perspectives for Targeted Personalized Therapies

Targeting Antitumor Immune Response for Enhancing the Efficacy of Photodynamic Therapy of Cancer: Recent Advances and Future Perspectives

The Photosensitizer Temoporfin (mTHPC) – Chemical, Pre‐clinical and Clinical Developments in the Last Decade†‡

Contact Info

Product

Resources

About

The Photosensitizer Temoporfin (mTHPC) – Chemical, Pre‐clinical and Clinical Developments in the Last Decade^†^‡